Status:
UNKNOWN
ERAS® Guidelines Validation of CRS With or Without HIPEC
Lead Sponsor:
Hospices Civils de Lyon
Conditions:
Peritoneal Diseases
Eligibility:
All Genders
18+ years
Brief Summary
Enhanced recovery after surgery (ERAS®) pathways have been shown to considerably reduce complications, length of stay and costs after most of surgical procedures by standardised application of best ev...
Detailed Description
The study includes two succesive phases interrupted by a stage to implement ERAS® guidelines.
Eligibility Criteria
Inclusion
- Adults female and male patients (\> 18 year-old)
- Peritoneal cancer from colorectal, ovarian, gastric, appendix origin and primitive peritoneal cancer (peritoneal mesothelioma)
- Multidisciplinary team meeting validation for CRS/HIPEC
- Informed and signed surgical consent
Exclusion
- Patients without peritoneal cancer
- Patients with peritoneal cancer and extended extraperitoneal metastases contraindicating for CRS with or without HIPEC
- No informed consent signed
Key Trial Info
Start Date :
October 1 2021
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
August 31 2022
Estimated Enrollment :
288 Patients enrolled
Trial Details
Trial ID
NCT05185791
Start Date
October 1 2021
End Date
August 31 2022
Last Update
January 11 2022
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Texas Southwestern Medical Center
Dallas, Texas, United States, 75390
2
University of Calgary, Arnie Charbonneau Cancer Institute
Calgary, Alberta, Canada, T2N 1N4
3
Lausanne University Hospital
Lausanne, Switzerland, 1011